Kenneth Cohen to Proto-Oncogene Proteins c-myc
This is a "connection" page, showing publications Kenneth Cohen has written about Proto-Oncogene Proteins c-myc.
Connection Strength
0.538
-
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Adv. 2025 Nov 11; 9(21):5665-5675.
Score: 0.220
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.138
-
The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol Dis. 2010 Dec 15; 45(4):317-23.
Score: 0.077
-
Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004 May; 63(5):441-9.
Score: 0.049
-
Transformation by the Bmi-1 oncoprotein correlates with its subnuclear localization but not its transcriptional suppression activity. Mol Cell Biol. 1996 Oct; 16(10):5527-35.
Score: 0.029
-
Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci U S A. 1994 Jul 19; 91(15):6875-9.
Score: 0.025